Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword
Authors
Keywords
-
Journal
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 35, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-09-27
DOI
10.1186/s13046-016-0433-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer
- (2016) Giorgio Scagliotti et al. INVESTIGATIONAL NEW DRUGS
- The Fcp1-Wee1-Cdk1 axis affects spindle assembly checkpoint robustness and sensitivity to antimicrotubule cancer drugs
- (2015) R Visconti et al. CELL DEATH AND DIFFERENTIATION
- Will Targeting Chk1 Have a Role in the Future of Cancer Therapy?
- (2015) Nandini Sakurikar et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors
- (2015) Adil I. Daud et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors
- (2015) Khanh Do et al. JOURNAL OF CLINICAL ONCOLOGY
- Elevated kinesin family member 26B is a prognostic biomarker and a potential therapeutic target for colorectal cancer
- (2015) Jingtao Wang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Fcp1 phosphatase controls Greatwall kinase to promote PP2A-B55 activation and mitotic progression
- (2015) Rosa Della Monica et al. eLife
- Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma
- (2015) Rosaria Chilà et al. Oncotarget
- Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors
- (2014) Edward Sausville et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- CDK1 switches mitotic arrest to apoptosis by phosphorylating Bcl-2/Bax family proteins during treatment with microtubule interfering agents
- (2014) Lingli Zhou et al. CELL BIOLOGY INTERNATIONAL
- Inhibition of Aurora B by CCT137690 sensitizes colorectal cells to radiotherapy
- (2014) Xiaoyu Wu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Identification of a mitotic death signature in cancer cell lines
- (2013) Nandini Sakurikar et al. CANCER LETTERS
- Long non-coding RNA ANRIL (CDKN2B-AS) is induced by the ATM-E2F1 signaling pathway
- (2013) Guohui Wan et al. CELLULAR SIGNALLING
- Mitosis and apoptosis: how is the balance set?
- (2013) Caroline H Topham et al. CURRENT OPINION IN CELL BIOLOGY
- Tumour selective targeting of cell cycle kinases for cancer treatment
- (2013) Marieke Aarts et al. CURRENT OPINION IN PHARMACOLOGY
- Advances in the discovery of kinesin spindle protein (Eg5) inhibitors as antitumor agents
- (2013) Hala Bakr El-Nassan EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy
- (2013) A. D. Guertin et al. MOLECULAR CANCER THERAPEUTICS
- The ATM protein kinase: regulating the cellular response to genotoxic stress and more
- (2013) Yosef Shiloh et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer
- (2012) Cynthia X. Ma et al. BREAST CANCER RESEARCH AND TREATMENT
- The end of mitosis from a phosphatase perspective
- (2012) Roberta Visconti et al. CELL CYCLE
- CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs
- (2012) M. I. Walton et al. CLINICAL CANCER RESEARCH
- Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias
- (2012) J. E. Karp et al. CLINICAL CANCER RESEARCH
- Mechanisms of replication fork protection: a safeguard for genome stability
- (2012) Alessia Errico et al. CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Cyclin-Dependent Kinase Suppression by WEE1 Kinase Protects the Genome through Control of Replication Initiation and Nucleotide Consumption
- (2012) H. Beck et al. MOLECULAR AND CELLULAR BIOLOGY
- WEE1 Kinase Inhibition Enhances the Radiation Response of Diffuse Intrinsic Pontine Gliomas
- (2012) V. Caretti et al. MOLECULAR CANCER THERAPEUTICS
- Fcp1-dependent dephosphorylation is required for M-phase-promoting factor inactivation at mitosis exit
- (2012) Roberta Visconti et al. Nature Communications
- Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
- (2012) Marieke Aarts et al. Cancer Discovery
- Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines
- (2011) A Peasland et al. BRITISH JOURNAL OF CANCER
- MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts
- (2011) N. V. Rajeshkumar et al. CLINICAL CANCER RESEARCH
- MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells
- (2011) K. A. Bridges et al. CLINICAL CANCER RESEARCH
- Peptidyl Prolyl Isomerase, Pin1 is a Potential Target for Enhancing the Therapeutic Efficacy of Etoposide
- (2011) R. Mathur et al. CURRENT CANCER DRUG TARGETS
- Targeting the S and G2 checkpoint to treat cancer
- (2011) Tao Chen et al. DRUG DISCOVERY TODAY
- MK1775, a Selective Wee1 Inhibitor, Shows Single-Agent Antitumor Activity against Sarcoma Cells
- (2011) J. M. Kreahling et al. MOLECULAR CANCER THERAPEUTICS
- Preclinical Development of the Novel Chk1 Inhibitor SCH900776 in Combination with DNA-Damaging Agents and Antimetabolites
- (2011) R. Montano et al. MOLECULAR CANCER THERAPEUTICS
- Mitotic catastrophe: a mechanism for avoiding genomic instability
- (2011) Ilio Vitale et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- miRNA response to DNA damage
- (2011) Guohui Wan et al. TRENDS IN BIOCHEMICAL SCIENCES
- MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil
- (2010) Hiroshi Hirai et al. CANCER BIOLOGY & THERAPY
- Phosphorylation of Mcl-1 by CDK1–cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest
- (2010) Margaret E Harley et al. EMBO JOURNAL
- A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial
- (2010) Tianhong Li et al. INVESTIGATIONAL NEW DRUGS
- How do anti-mitotic drugs kill cancer cells?
- (2009) K. E. Gascoigne et al. JOURNAL OF CELL SCIENCE
- The expression of PLK-1 in cervical carcinoma: a possible target for enhancing chemosensitivity
- (2009) Yuan Zhang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells
- (2009) L. A. Parsels et al. MOLECULAR CANCER THERAPEUTICS
- Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents
- (2009) H. Hirai et al. MOLECULAR CANCER THERAPEUTICS
- The DNA-damage response in human biology and disease
- (2009) Stephen P. Jackson et al. NATURE
- Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1
- (2008) A. Blasina et al. MOLECULAR CANCER THERAPEUTICS
- ATR: an essential regulator of genome integrity
- (2008) Karlene A. Cimprich et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started